XIANGXUE PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.67 CNY | -1.87% |
|
+1.38% | -28.74% |
| Sales 2022 | 2.19B 302M 25.18B | Sales 2023 | 2.3B 318M 26.47B | Capitalization | 3.41B 470M 39.21B |
|---|---|---|---|---|---|
| Net income 2022 | -533M -73.62M -6.14B | Net income 2023 | -389M -53.73M -4.48B | EV / Sales 2022 | 2.86 x |
| Net Debt 2022 | 2.29B 316M 26.38B | Net Debt 2023 | 2.28B 315M 26.29B | EV / Sales 2023 | 2.47 x |
| P/E ratio 2022 |
-7.49
x | P/E ratio 2023 |
-8.73
x | Employees | 2,417 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 37.6% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.87% | ||
| 1 week | +1.38% | ||
| 1 month | -15.63% | ||
| 3 months | -1.08% | ||
| 6 months | -33.27% | ||
| Current year | -28.74% |
1 week
3.60
3.76
1 month
3.324.19
Current year
3.005.35
1 year
3.006.45
3 years
3.009.79
5 years
3.0014.48
10 years
3.0051.41
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Hui Wang
CEO | Chief Executive Officer | 62 | 16/97/16 |
Wei Hua Huang
CHM | Chairman | 53 | 01/05/01 |
Zhi Ying Kang
CTO | Chief Tech/Sci/R&D Officer | 47 | 28/19/28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong Hui Wang
CEO | Chief Executive Officer | 62 | 16/97/16 |
Jun Hui Chen
BRD | Director/Board Member | 57 | 28/12/28 |
Wen Jin Chen
BRD | Director/Board Member | 51 | 24/22/24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 3.67 | -1.87% | 13,332,250 |
| 29/24/29 | 3.74 | +3.60% | 13,754,280 |
| 26/24/26 | 3.61 | -0.28% | 8,034,628 |
| 25/24/25 | 3.62 | +1.12% | 8,187,633 |
| 24/24/24 | 3.58 | +0.85% | 6,657,803 |
End-of-day quote Shenzhen S.E., April 30, 2024
More quotes
XIANGXUE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the research, development, production and distribution of traditional Chinese medicines and herbal decoction pieces. The Company's main products include antiviral oral liquids, indigowoad root granules, Exocarpium Citri Reticulatae series Chinese patent drugs and herbal decoction pieces, among others. The Company is also involved in the manufacture and sale of medical devices, health products, soft drinks and biological products. The Company distributes its products in domestic market.
Sector
Pharmaceuticals
Calendar
30/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -28.74% | 335M | |
| +39.33% | 6.11B | |
| -18.38% | 4.35B | |
| -9.17% | 3.18B | |
| +3.98% | 3.15B | |
| -3.41% | 2.51B | |
| +48.74% | 1.98B | |
| -4.82% | 1.74B | |
| -1.24% | 1.63B | |
| -8.96% | 1.6B |
- Stock Market
- Equities
- 300147 Stock
